Tango Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 5.77 million compared to USD 18.15 million a year ago. Net loss was USD 24.86 million compared to USD 4.49 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 0.09 a year ago.
For the six months, revenue was USD 11.53 million compared to USD 24.54 million a year ago. Net loss was USD 50.07 million compared to USD 16.6 million a year ago. Basic loss per share from continuing operations was USD 0.57 compared to USD 0.37 a year ago.